Fuji Pharma Co., Ltd.

As of March 31, 2026, Fuji Pharma Co., Ltd. carries a market capitalization of 61.85B, placing it among publicly traded companies globally. Its enterprise value stands at 80.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fuji Pharma Co., Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of March 31, 2026, Fuji Pharma Co., Ltd. has 26.12M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Fuji Pharma Co., Ltd. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 23, 2026, Fuji Pharma Co., Ltd.'s stock has gained approximately 14.41% over the past 52 weeks. The 50-day moving average sits at 1,809.50, while the 200-day moving average is 2,058.86.

As of March 31, 2026, Fuji Pharma Co., Ltd. holds 10.89B in cash and equivalents against 29.62B in total debt, resulting in a net debt position of 14.31B. Total book value stands at 51.36B, with working capital of 22.02B providing operational flexibility.

Fuji Pharma Co., Ltd.'s most recent stock split took place on June 27, 2018 with a 1:2 split ratio.